EQ
EQ.O
—
NASDAQ
Pharmaceuticals & Medical Research
Equillium Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
141,6M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
-78,3 %
Net margin
—
Debt / equity
0,00
Beta
—
52w range
—
Volume
7,7k
Day range
$2,26–$2,74
Prev close
$2,32
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Equillium Inc is a biotechnology company focused on the development of novel therapeutics for the treatment of autoimmune and inflammatory diseases.
Business. Equillium Inc (EQ.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY8 analysts
7 buy1 hold0 sell
Avg 12m price target7,14
Analyst recommendations
8 analysts · consensus BuyBuy7
Hold1
Sell0
12-month price target
7,14
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
8 analysts · indicative
Ownership→
JANUS HENDERSON GROUP PLC
largest disclosed fund holder
Profitability→
-78,3 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to EQ.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Equillium Inc (EQ.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
AI synthesis
GENERATEDEquillium Inc has a market capitalization of $163.76 million and a price-to-book ratio of 5.73, indicating that the market is valuing the company at a premium to its book value. The company's liquidity position is strong, with $30.28 million in cash and equivalents and a current ratio of 10.58, suggesting that it has ample short-term liquidity to cover its liabilities. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating that it is entirely equity-financed.
The company's profitability metrics are negative, with a return on equity of -7.83% and a return on assets of -7.02%, reflecting a lack of profitability and operational efficiency. The company reported a net loss of $22.40 million and an operating loss of $23.63 million, with no revenue reported, indicating that it is in the early stages of commercialization or still in development. The company's operating cash flow is negative at -$22.75 million, and its free cash flow is also negative at -$22.33 million, suggesting that it is not generating positive cash flows from operations.
Equillium Inc does not report revenue by segment or geographic region, so it is not possible to assess the concentration of its revenue across different business lines or geographic markets. The company's capital expenditures are minimal at -$48,000, indicating that it is not investing heavily in physical assets at this time.
The company's growth trajectory is not yet defined, as it has not reported any revenue and is currently in a net loss position. Analysts have provided a mean price target of $7.14 and a median price target of $6.00, with a mean recommendation of 1.62, indicating a generally positive outlook from the analyst community. The company has four strong-buy ratings, three buy ratings, and one hold rating, suggesting that the majority of analysts see potential in the company's future performance.
The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company has a low dilution potential, and no adjustments have been applied to its valuation metrics, indicating that there are no significant dilutive events on the horizon.
There are no recent events or filings that have been disclosed in the provided data, so it is not possible to assess the company's recent performance or strategic direction based on public disclosures.
Key takeaways
- Equillium Inc is a biotechnology company with no reported revenue and is currently in a net loss position.
- The company has a strong liquidity position with $30.28 million in cash and equivalents and a current ratio of 10.58.
- The company's profitability metrics are negative, with a return on equity of -7.83% and a return on assets of -7.02%.
- Analysts have provided a generally positive outlook, with a mean price target of $7.14 and a median price target of $6.00.
- The company has low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$2,24
Market cap
$163.8M
Enterprise valueⓘ
$133.5M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
5.7x
P / Tangible bookⓘ
5.7x
Tangible book
$28.6M
Net cashⓘ
$30.3M
Current ratioⓘ
10.6
Debt / equityⓘ
0.0
ROAⓘ
-70.2%
ROEⓘ
-78.3%
Cash conversionⓘ
102.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships3 disclosed relationships · 1 type · extracted from filings & disclosures
Subsidiaries3
EX21:2d02d4fcc9b0EX21:2d02d4fcc9b0Subsidiarie97%
EX21:68916e98ff4bEX21:68916e98ff4bSubsidiarie97%
EX21:852079f5f741EX21:852079f5f741Subsidiarie97%
Supply chain
— missing data
Peer comparison
Peer comparison8 peers · vs EQ · multiples and returns
KL
KLAR—
KLAR.ST
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BN
BNTX—
Biontech SE
$92,25
23,3B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
EX
EXEL—
Exelixis Inc
$55,06
14,7B USDP/E
19,5x
— vs self
Div yield
—
— vs self
ROE
40,4 %
+118,8 vs self
MD
MDGL—
Madrigal Pharmaceuticals Inc
$482,00
11,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-47,8 %
+30,5 vs self
IN
INSM—
Insmed Inc
$107,46
23,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-160,2 %
-81,9 vs self
VC
VCYT—
Veracyte Inc
$45,30
3,6B USDP/E
55,5x
— vs self
Div yield
—
— vs self
ROE
5,1 %
+83,4 vs self
MD
MDXG—
Mimedx Group Inc
$4,27
636,0M USDP/E
11,1x
— vs self
Div yield
—
— vs self
ROE
18,9 %
+97,3 vs self
AV
AVIR—
Atea Pharmaceuticals Inc
$4,61
—P/E
—
— vs self
Div yield
—
— vs self
ROE
-57,5 %
+20,8 vs self
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-0,21
Predicted surprise
+0,00
Beat probability
45 %
Analysts
8
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-16 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,21 |
| Revenue | —no estimate | —no estimate | 0 USD |
| Operating income | —no estimate | —no estimate | -26,8M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution8 analysts
Strong buy4
Buy3
Hold1
Sell0
Strong sell0
12-month price target$7,14 · Median $6,00
Low $4,00High $12,00
Operating income · consensus-26,8M USD
EPS surprise
−85,7 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$4,00
Mean$7,14
Median$6,00
High$12,00
Spot$2,24
+218.9 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
ROE-78,3 %Below median
D/E0,00Above median
Cash Conv1,02Above median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 7 435 973 sh14 exercises · 13 grants9 insiders
- Sr. Vice President and COO · Employee Stock Option (right to buy) → Common StockDisposed 14 584 @ $0,79exercise · 2026-06-05
- Sr. Vice President and COO · Employee Stock Option (right to buy) → Common StockDisposed 14 583 @ $0,79exercise · 2026-05-28
- Sr. Vice President and COO · Employee Stock Option (right to buy) → Common StockDisposed 15 625 @ $0,79exercise · 2026-05-28
- Director · Director Stock Option (right to buy) → Common StockAcquired 70 000 @ $2,84grant · 2026-05-28
- Sr. Vice President and COO · Employee Stock Option (right to buy) → Common StockDisposed 7 292 @ $0,73exercise · 2026-05-28
- Principal Accounting Officer · Employee Stock Option (right to buy) → Common StockDisposed 65 000 @ $0,79exercise · 2026-05-28
- Director · Director Stock Option (right to buy) → Common StockAcquired 70 000 @ $2,84grant · 2026-05-28
- Director · Director Stock Option (right to buy) → Common StockAcquired 70 000 @ $2,84grant · 2026-05-28
- Director, CHAIRMAN · Director stock option (right to buy) → Common StockAcquired 70 000 @ $2,84grant · 2026-05-28
- Director · Director Stock Option (right to buy) → Common StockAcquired 70 000 @ $2,84grant · 2026-05-28
- Sr. Vice President and COO · Employee Stock Option (right to buy) → Common StockDisposed 48 512 @ $0,77exercise · 2026-05-28
- Sr. Vice President and COO · Employee Stock Option (right to buy) → Common StockDisposed 9 821 @ $0,77exercise · 2026-05-27
- Sr. Vice President and COO · Employee Stock Option (right to buy) → Common StockDisposed 120 312 @ $0,79exercise · 2026-03-13
- Sr. Vice President and COO · Employee Stock Option (right to buy) → Common StockDisposed 75 000 @ $0,79exercise · 2026-03-09
- Sr. Vice President and COO · Employee Stock Option (right to buy) → Common StockDisposed 35 695 @ $0,79exercise · 2026-03-09
- Sr. Vice President and COO · Employee Stock Option (right to buy) → Common StockDisposed 41 666 @ $0,79exercise · 2026-03-09
- Sr. Vice President and COO · Employee Stock Option (right to buy) → Common StockDisposed 109 375 @ $0,79exercise · 2026-02-19
- Sr. Vice President and COO · Employee Stock Option (right to buy) → Common StockDisposed 76 562 @ $0,73exercise · 2026-02-19
- Principal Accounting Officer · Employee Stock Option (right to buy) → Common StockAcquired 450 000 @ $1,31grant · 2026-01-07
- Sr. Vice President and COO · Employee Stock Option (right to buy) → Common StockAcquired 500 000 @ $1,31grant · 2026-01-07
- Director, Chief Executive Officer, 10% owner · Employee Stock Option (right to buy) → Common StockAcquired 1 750 000 @ $1,31grant · 2026-01-07
- Director, President and CSO · Employee Stock Option (right to buy) → Common StockAcquired 1 150 000 @ $1,31grant · 2026-01-07
- Sr. Vice President and COO · Employee Stock Option (right to buy) → Common StockDisposed 100 000 @ $0,79exercise · 2025-12-23
- Director, Chief Scientific Officer · Employee Stock Option (right to buy) → Common StockAcquired 1 025 000 @ $1,74grant · 2025-08-29
- Principal Accounting Officer · Employee Stock Option (right to buy) → Common StockAcquired 525 000 @ $1,74grant · 2025-08-29
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Source documents
- Equillium Inc Market data — financials · 2026-05-27
- Equillium Inc Market data — analyst estimates · 2026-05-27
- Equillium Inc Market data — ESG · 2026-05-27
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,01 %$13M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2025-12-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Leadership
- Bruce D. SteelPresident, Chief Executive Officer, Director
Insider activity
Net selling0 buys · 18 sellsnet -$2,4M3 insiders · last 365d
- Sr. Vice President and COO · Common StockOther 14 584 @ $0,79$11K · 2026-06-05
- President and CSO · Common StockSold 30 975 @ $2,94$91K · 2026-06-05
- Sr. Vice President and COO · Common StockSold 14 584 @ $2,93$43K · 2026-06-05
- President and CSO · Common StockSold 200 000 @ $3,16$633K · 2026-06-04
- Sr. Vice President and COO · Common StockOther 15 625 @ $0,79$12K · 2026-05-28
- Sr. Vice President and COO · Common StockSold 55 604 @ $2,70$150K · 2026-05-28
- Sr. Vice President and COO · Common StockSold 200 @ $2,71$542 · 2026-05-28
- Sr. Vice President and COO · Common StockOther 14 583 @ $0,79$11K · 2026-05-28
- Sr. Vice President and COO · Common StockSold 30 208 @ $2,98$90K · 2026-05-28
- Principal Accounting Officer · Common StockOther 65 000 @ $0,79$51K · 2026-05-28
- Principal Accounting Officer · Common StockSold 65 000 @ $2,95$192K · 2026-05-28
- Sr. Vice President and COO · Common StockOther 7 292 @ $0,73$5K · 2026-05-28
- Sr. Vice President and COO · Common StockOther 48 512 @ $0,77$37K · 2026-05-28
- Sr. Vice President and COO · Common StockOther 9 821 @ $0,77$8K · 2026-05-27
- Sr. Vice President and COO · Common StockSold 9 821 @ $2,70$27K · 2026-05-27
- Sr. Vice President and COO · Common StockSold 120 312 @ $2,50$301K · 2026-03-13
- Sr. Vice President and COO · Common StockOther 120 312 @ $0,79$94K · 2026-03-13
- Sr. Vice President and COO · Common StockOther 35 695 @ $0,79$28K · 2026-03-09
- Sr. Vice President and COO · Common StockSold 181 219 @ $2,00$362K · 2026-03-09
- Sr. Vice President and COO · Common StockOther 75 000 @ $0,79$59K · 2026-03-09
- Sr. Vice President and COO · Common StockOther 41 666 @ $0,79$33K · 2026-03-09
- Sr. Vice President and COO · Common StockOther 76 562 @ $0,73$56K · 2026-02-19
- Sr. Vice President and COO · Common StockOther 109 375 @ $0,79$86K · 2026-02-19
- Sr. Vice President and COO · Common StockSold 109 375 @ $1,78$195K · 2026-02-19
- Sr. Vice President and COO · Common StockSold 76 562 @ $1,74$133K · 2026-02-19
Short positioning
5.6Mshares short+8.9% vs prior
4.54days to cover
45.2%short of daily vol
1.5Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
EQ.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorSubsidiaries
Evidence & claims
From filings & derived data- Debt-to-equity (FY 2025-12-31): 0.12xDerived (calculated)
- Return on equity (FY 2025-12-31): -78.3%Derived (calculated)
- Return on assets (FY 2025-12-31): -70.2%Derived (calculated)
- Current ratio (FY 2025-12-31): 10.58xDerived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -43.5%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 67.4%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -177.6%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -19.6%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -185.8%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 50.0%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 24.5%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -49.7%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -69.6%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -69.6%Derived (calculated)
- EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
- Pre-tax income (annual): USD -22.4MSEC XBRL filing
- Operating cash flow (annual): USD -22.75MSEC XBRL filing
- Total assets (annual): USD 31.89MSEC XBRL filing
- Capex (annual): USD 48KSEC XBRL filing
- Shareholders' equity (annual): USD 28.6MSEC XBRL filing
- Operating income (annual): USD -23.63MSEC XBRL filing
- Cash & equivalents (annual): USD 30.28MSEC XBRL filing
- Total liabilities (annual): USD 3.29MSEC XBRL filing
- Current assets (annual): USD 31.04MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-05 00:00 UTCINSIDER5 insider transactions — 2026-06 · net sell $755k 1 derivative
2026-06-05INSIDERZedelmayer Christine transacted 14.6k sh — Sr. Vice President and COO ~$11k
2026-06-05INSIDERZedelmayer Christine sold 14.6k sh — Sr. Vice President and COO ~$43k
2026-06-05INSIDERConnelly Stephen sold 31.0k sh — President and CSO ~$91k
2026-06-05INSIDERZedelmayer Christine disposed of 14.6k sh Employee Stock Option (right to buy) — Sr. Vice President and COO
2026-06-04INSIDERConnelly Stephen sold 200.0k sh — President and CSO ~$633k
2026-05-28 00:00 UTCINSIDER22 insider transactions — 2026-05 · net sell $334k 11 derivative
2026-05-28INSIDERZedelmayer Christine transacted 15.6k sh — Sr. Vice President and COO ~$12k
2026-05-28INSIDERTom Penny transacted 65.0k sh — Principal Accounting Officer ~$51k
2026-05-28INSIDERTom Penny sold 65.0k sh — Principal Accounting Officer ~$192k
2026-05-28INSIDERZedelmayer Christine transacted 7.3k sh — Sr. Vice President and COO ~$5k
2026-05-28INSIDERZedelmayer Christine transacted 48.5k sh — Sr. Vice President and COO ~$37k
2026-05-28INSIDERZedelmayer Christine sold 55.6k sh — Sr. Vice President and COO ~$150k
2026-05-28INSIDERZedelmayer Christine sold 200 sh — Sr. Vice President and COO ~$1k
2026-05-28INSIDERZedelmayer Christine transacted 14.6k sh — Sr. Vice President and COO ~$11k
2026-05-28INSIDERZedelmayer Christine sold 30.2k sh — Sr. Vice President and COO ~$90k
2026-05-28INSIDERDEMSKI MARTHA J acquired 70.0k sh Director Stock Option (right to buy) — Director
2026-05-28INSIDERPruzanski Mark acquired 70.0k sh Director Stock Option (right to buy) — Director
2026-05-28INSIDERBRADBURY DANIEL acquired 70.0k sh Director stock option (right to buy) — Director, CHAIRMAN
2026-05-28INSIDERZedelmayer Christine disposed of 7.3k sh Employee Stock Option (right to buy) — Sr. Vice President and COO
2026-05-28INSIDERZedelmayer Christine disposed of 48.5k sh Employee Stock Option (right to buy) — Sr. Vice President and COO
2026-05-28INSIDERZedelmayer Christine disposed of 14.6k sh Employee Stock Option (right to buy) — Sr. Vice President and COO
2026-05-28INSIDERMcDermott Charles Douglas acquired 70.0k sh Director Stock Option (right to buy) — Director
2026-05-28INSIDERZedelmayer Christine disposed of 15.6k sh Employee Stock Option (right to buy) — Sr. Vice President and COO
2026-05-28INSIDERTroupin Barbara acquired 70.0k sh Director Stock Option (right to buy) — Director
2026-05-28INSIDERTom Penny disposed of 65.0k sh Employee Stock Option (right to buy) — Principal Accounting Officer
2026-05-27INSIDERZedelmayer Christine transacted 9.8k sh — Sr. Vice President and COO ~$8k
2026-05-27INSIDERZedelmayer Christine sold 9.8k sh — Sr. Vice President and COO ~$27k
2026-05-27INSIDERZedelmayer Christine disposed of 9.8k sh Employee Stock Option (right to buy) — Sr. Vice President and COO
2026-03-13 00:00 UTCINSIDER10 insider transactions — 2026-03 · net sell $449k 4 derivative
2026-03-13INSIDERZedelmayer Christine transacted 120.3k sh — Sr. Vice President and COO ~$94k
Showing the 40 most recent of 62 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage